Activating mutations in the epidermal growth factor receptor (EGFR) gene, leading to aberrant EGFR signaling, render non-small cell lung cancer (NSCLC) tumors highly sensitive to targeted treatment with EGFR tyrosine kinase inhibitors (TKIs) (1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.